WALTHAM, Mass., June 28, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, announced today that it has completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash.
The Anatomical Pathology business, with approximately 1200 employees in the U.S., Europe and Asia, generated approximately $350 million in annual revenue and was part of Thermo Fisher’s Specialty Diagnostics Segment.
Date: July 08, 2019
Source: Thermo Fisher Scientific
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
